- Home
- BEAM vs ADEA Comparison
BEAM vs ADEA Comparison
Compare BEAM & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAM | ADEA |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BEAM | ADEA |
|---|---|---|
| Price | $23.29 | $20.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $52.15 | $43.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | ★ 82.31 | 73.68 |
| EPS | N/A | ★ 0.35 |
| Revenue | $24,000.00 | ★ $443,386,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.19 | $8.42 |
| P/E Ratio | ★ N/A | $62.09 |
| Revenue Growth | ★ 33.33 | 17.91 |
| 52 Week Low | $20.23 | $11.61 |
| 52 Week High | $38.26 | $34.34 |
Technical Indicators
Market Signals| Indicator | BEAM | ADEA |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 24.37 |
| Support Level | $22.49 | $17.07 |
| Resistance Level | $26.72 | $26.18 |
| Average True Range (ATR) | 1.17 | 1.06 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 4.89 | 1.79 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.